United Therapeutics | UTHR - Des Atouts





Des Atouts Changement Date
Amarin USD 645.76M 25.01M 2026-03
Ardelyx USD 504.51M 2.9M 2026-03
Baxter International USD 19.85B 209M 2026-03
Bayer EUR 107.94B 3.4B 2026-03
BioCryst Pharmaceuticals USD 465.05M 49.11M 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Emergent BioSolutions USD 1.82B 69.9M 2023-12
Esperion Therapeutics USD 462.53M 3.36M 2026-03
Gilead Sciences USD 56.28B 2.74B 2026-03
GlaxoSmithKline GBP 62.87B 1.75B 2026-03
Halozyme Therapeutics USD 2.67B 147.4M 2026-03
Insmed USD 2.08B 188.7M 2026-03
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
J&J USD 200.89B 1.68B 2026-03
Lexicon Pharmaceuticals USD 268.82M 83.83M 2026-03
Moderna USD 11.49B 850M 2026-03
Omeros USD 200.57M 34.59M 2025-06
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.87B 29.66M 2026-03
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sarepta Therapeutics USD 3.18B 170.77M 2026-03
Teva Pharmaceutical Industries USD 40.04B 708M 2026-03
United Therapeutics USD 6.71B 1.17B 2026-03
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03